51 related articles for article (PubMed ID: 21041072)
21. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
Tokar EJ; Ancrile BB; Ablin RJ; Webber MM
J Exp Ther Oncol; 2006; 5(4):323-33. PubMed ID: 17024972
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Campbell MJ; Reddy GS; Koeffler HP
J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
[TBL] [Abstract][Full Text] [Related]
23. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
Moffatt KA; Johannes WU; Miller GJ
Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
[TBL] [Abstract][Full Text] [Related]
24. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.
Yang L; Yang J; Venkateswarlu S; Ko T; Brattain MG
J Cell Physiol; 2001 Sep; 188(3):383-93. PubMed ID: 11473365
[TBL] [Abstract][Full Text] [Related]
25. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
26. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
Myrthue A; Rademacher BL; Pittsenbarger J; Kutyba-Brooks B; Gantner M; Qian DZ; Beer TM
Clin Cancer Res; 2008 Jun; 14(11):3562-70. PubMed ID: 18519790
[TBL] [Abstract][Full Text] [Related]
27. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
[TBL] [Abstract][Full Text] [Related]
28. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.
Zha S; Ferdinandusse S; Hicks JL; Denis S; Dunn TA; Wanders RJ; Luo J; De Marzo AM; Isaacs WB
Prostate; 2005 Jun; 63(4):316-23. PubMed ID: 15599942
[TBL] [Abstract][Full Text] [Related]
29. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
30. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
32. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
Stewart LV; Weigel NL
Prostate; 2005 Jun; 64(1):9-19. PubMed ID: 15651061
[TBL] [Abstract][Full Text] [Related]
33. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
Pálmer HG; Sánchez-Carbayo M; Ordóñez-Morán P; Larriba MJ; Cordón-Cardó C; Muñoz A
Cancer Res; 2003 Nov; 63(22):7799-806. PubMed ID: 14633706
[TBL] [Abstract][Full Text] [Related]
34. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.
Seth D; Shaw K; Jazayeri J; Leedman PJ
Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
36. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE.
Tovar Sepulveda VA; Falzon M
Mol Cell Endocrinol; 2003 Jun; 204(1-2):51-64. PubMed ID: 12850281
[TBL] [Abstract][Full Text] [Related]
38. Re: Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
Atala A
J Urol; 2018 May; 199(5):1115-1116. PubMed ID: 29677904
[No Abstract] [Full Text] [Related]
39. Expression and vitamin D3 regulation of long-chain fatty-acid-CoA ligase 3 in human prostate cancer cells.
Qiao S; Tuohimaa P
Prostaglandins Leukot Essent Fatty Acids; 2011; 84(1-2):19-23. PubMed ID: 21041072
[TBL] [Abstract][Full Text] [Related]
40. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.
Qiao S; Tuohimaa P
Biochem Biophys Res Commun; 2004 Jun; 319(2):358-68. PubMed ID: 15178414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
